Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736449 · ClinicalTrials.gov registry record · Phase 4
Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management
A Phase 4 study, sponsored by Arrowhead Regional Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT01736449 is a Phase 4 study that has completed, run by Arrowhead Regional Medical Center. The registered enrollment target is 31 participants.
The verdict
NCT01736449, a Phase 4 study, has completed, sponsored by Arrowhead Regional Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
A pterygium is a fibrovascular growth originating from the conjunctiva that grows onto the surface of the cornea. Frequently, these pterygia will recur even after surgical resection. Bevacizumab is an inhibitor of angiogenesis, which is needed for recurrent growth. The use of bevacizumab is poorly understood in inhibiting pterygium growth. The objective of this study is to compare the effects of wound healing and recurrence rates in postoperative bevacizumab versus pterygium excision alone.
Interventions
- DRUG Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01736449
The ClinicalTrials.gov registry entry for NCT01736449 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arrowhead Regional Medical Center, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bevacizumab is the first listed.
NCT01736449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01736449 about?
NCT01736449 is a clinical study titled "Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management". A pterygium is a fibrovascular growth originating from the conjunctiva that grows onto the surface of the cornea. Frequently, these pterygia will recur even after surgical resection. Bevacizumab is an inhibitor of angiogenesis, which is needed for recurrent growth. The use of bevacizumab is poorly u...
What is the current status of trial NCT01736449?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2011-04. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01736449?
The interventions under investigation include: Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT01736449?
This trial is sponsored by Arrowhead Regional Medical Center, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.